Sensus Healthcare Inc (SRTS)
Official siteHEALTHCARE • MEDICAL DEVICES • NASDAQ
Market Cap: $38.27M
Last updated: Nov 17, 2026 at 11:05 AM ET
Sensus Healthcare Inc (SRTS) Financials: Revenue, Profit and Cash Flow
Sensus Healthcare reported revenue of $27.48M for the fiscal year ended Dec 31, 2025, down 34.3% from the year before. That year, net income was -$7.72M with a net margin of -28.1%, operating cash flow was $528.00K and free cash flow was $332.00K. The quarter ended Sep 30, 2026 had revenue of $6.00M and net income of -$1.49M.
Revenue and Margins
The operating margin was -37.5% in the fiscal year ended Dec 2025. Over the 9 years to Dec 2025, revenue grew from $14.81M, a compound annual rate of 7.1%.
| Fiscal year | Revenue | Growth | Gross margin | Operating margin | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | $27.48M | -34.3% | 43.2% | -37.5% | -28.1% |
| Dec 2024 | $41.81M | +71.3% | 58.4% | 19.4% | 15.9% |
| Dec 2023 | $24.41M | -45.2% | 57.6% | -1.6% | 2.0% |
| Dec 2022 | $44.53M | +64.7% | 66.5% | 33.3% | 54.4% |
| Dec 2021 | $27.04M | +182.4% | 62.8% | 15.2% | 15.2% |
| Dec 2020 | $9.58M | -64.9% | 54.8% | -86.0% | -71.4% |
| Dec 2019 | $27.26M | +3.2% | 64.4% | -7.2% | -6.2% |
| Dec 2018 | $26.43M | +28.4% | 64.0% | -7.6% | -7.7% |
| Dec 2017 | $20.59M | +39.0% | 67.0% | -18.1% | -18.0% |
| Dec 2016 | $14.81M | N/A | 66.5% | -2.5% | -2.3% |
Income Statement
In the fiscal year ended Dec 2025, the company posted a net loss after a profit the year before. In the quarter ended Sep 2026, the net loss widened from the same quarter a year earlier.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $27.48M | $41.81M | $24.41M | $44.53M | $27.04M | $9.58M | $27.26M | $26.43M | $20.59M | $14.81M |
| Cost of revenue | $15.62M | $17.38M | $10.35M | $14.90M | $10.05M | $4.33M | $9.71M | $9.52M | $6.79M | $4.97M |
| Gross profit | $11.87M | $24.43M | $14.06M | $29.63M | $16.99M | $5.25M | $17.56M | $16.91M | $13.80M | $9.85M |
| Research and development | $7.78M | $4.22M | $3.68M | $3.46M | $3.44M | $4.16M | $6.42M | $6.26M | $5.49M | $1.82M |
| Operating income | -$10.31M | $8.09M | -$382.00K | $14.83M | $4.12M | -$8.23M | -$1.97M | -$2.01M | -$3.72M | -$363.12K |
| Net income | -$7.72M | $6.65M | $485.00K | $24.24M | $4.12M | -$6.84M | -$1.70M | -$2.02M | -$3.71M | -$346.45K |
| EBITDA | -$9.68M | $8.52M | $121.00K | $28.50M | $4.73M | -$6.92M | -$1.42M | -$1.35M | -$3.33M | -$25.54K |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $6.00M | $2.29M | $3.39M | $4.94M | $6.88M | $7.32M | $8.34M | $13.07M | $8.84M | $9.24M | $10.66M | $12.57M |
| Gross profit | $3.29M | $769.00K | $991.00K | $1.90M | $2.71M | $2.90M | $4.35M | $7.11M | $5.24M | $5.42M | $6.66M | $7.83M |
| Operating income | -$1.62M | -$3.18M | -$4.36M | -$3.15M | -$2.57M | -$1.94M | -$2.65M | $1.73M | $1.50M | $1.98M | $2.89M | $5.58M |
| Net income | -$1.49M | -$8.75M | -$2.63M | -$3.17M | -$943.00K | -$1.04M | -$2.57M | $1.55M | $1.22M | $1.61M | $2.27M | $4.21M |
Balance Sheet
As of Dec 2025, cash and equivalents exceeded short-term debt of $262.00K by $21.82M.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $53.04M | $62.16M | $53.71M | $56.73M | $32.24M | $28.01M | $36.92M | $33.25M | $18.84M | $18.95M |
| Current assets | $45.89M | $56.74M | $49.53M | $53.24M | $31.25M | $25.17M | $34.00M | $31.90M | $17.89M | $16.76M |
| Cash and equivalents | $22.08M | $22.06M | $23.15M | $25.52M | $14.52M | $14.91M | $8.10M | $12.48M | $10.09M | $5.04M |
| Total liabilities | $4.94M | $6.34M | $4.87M | $8.67M | $6.22M | $6.51M | $8.92M | $6.79M | $7.15M | $3.67M |
| Short-term debt | $262.00K | $204.00K | $187.00K | $190.00K | $51.00K | $0 | $309.52K | -$5.17M | $2.21M | -$2.76M |
| Long-term debt | N/A | N/A | N/A | N/A | N/A | $267.00K | $0 | N/A | $2.21M | $0 |
| Shareholder equity | $48.10M | $55.83M | $48.84M | $48.07M | $26.02M | $21.50M | $28.00M | $26.46M | $11.68M | $15.27M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $40.55M | $41.26M | $51.55M | $53.04M | $58.30M | $58.85M | $60.21M | $62.16M | $59.86M | $58.16M | $57.27M | $53.71M |
| Total liabilities | $5.11M | $4.40M | $6.00M | $4.94M | $7.10M | $6.79M | $7.18M | $6.34M | $5.73M | $5.26M | $6.07M | $4.87M |
| Cash and equivalents | $12.92M | $15.19M | $18.33M | $22.08M | $24.45M | $22.16M | $19.07M | $22.06M | $22.56M | $18.97M | $14.73M | $23.15M |
| Shareholder equity | $35.44M | $36.86M | $45.54M | $48.10M | $51.19M | $52.06M | $53.03M | $55.83M | $54.13M | $52.90M | $51.21M | $48.84M |
Cash Flow
In the fiscal year ended Dec 2025, free cash flow was 62.9% of operating cash flow. Share repurchases came to 90.4% of it.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $528.00K | -$831.00K | -$2.15M | -$1.41M | -$286.00K | -$434.00K | -$2.11M | -$8.56M | -$3.06M | -$3.85M |
| Capital expenditures | $196.00K | $276.00K | $229.00K | $159.00K | $128.00K | $359.00K | $400.59K | $854.83K | $287.59K | $286.00K |
| Free cash flow | $332.00K | -$1.11M | -$2.37M | -$1.57M | -$414.00K | -$793.00K | -$2.51M | -$9.42M | -$3.34M | -$4.14M |
| Dividends paid | N/A | N/A | N/A | $731.00K | N/A | $210.34K | N/A | N/A | $0 | $2.55M |
| Share repurchases | $300.00K | $0 | $27.00K | $3.00M | $0 | N/A | N/A | $1.40M | $0 | $2.13M |
| Investing cash flow | -$196.00K | -$276.00K | -$187.00K | $14.84M | $129.00K | $7.03M | -$4.90M | -$2.64M | $6.17M | -$7.85M |
| Financing cash flow | -$305.00K | $15.00K | -$40.00K | -$2.43M | -$231.00K | $211.00K | $2.62M | $13.60M | $1.93M | $8.68M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$2.26M | -$3.13M | -$3.75M | -$2.21M | $2.29M | $3.12M | -$2.68M | -$827.00K | $3.95M | $4.23M | -$8.19M | $2.67M |
| Capital expenditures | $5.00K | $8.00K | $3.00K | $158.00K | $4.00K | $27.00K | $7.00K | $297.00K | $337.00K | $3.00K | $233.00K | $229.00K |
| Free cash flow | -$2.27M | -$3.14M | -$3.76M | -$2.37M | $2.29M | $3.09M | -$2.68M | -$1.12M | $3.62M | $4.23M | -$8.42M | $2.44M |
Frequently Asked Questions About SRTS
What is Sensus Healthcare's annual revenue?
Sensus Healthcare reported revenue of $27.48M for the fiscal year ended Dec 31, 2025.
How fast is Sensus Healthcare's revenue growing?
Revenue was down 34.3% for the fiscal year ended Dec 31, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was -14.9%.
Is Sensus Healthcare profitable?
No. Sensus Healthcare reported net income of -$7.72M for the fiscal year ended Dec 31, 2025, with a net margin of -28.1%.
How much free cash flow does SRTS generate?
For the fiscal year ended Dec 31, 2025, operating cash flow of $528.00K minus capital expenditures of $196.00K produced free cash flow of $332.00K.
How much debt does Sensus Healthcare have?
The balance sheet dated Dec 31, 2025 reported short-term debt of $262.00K and cash and equivalents of $22.08M.
SRTS pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors